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INTRODUCTION
Glaucoma, a leading cause of blindness in the world, 
is a group of diseases characterized by progressive optic 
neuropathy with a particular pattern of visual field (VF) 
loss. While mechanical and vascular causes have been 
proposed, the cause of glaucoma remains unclear [1,2]. 
The mechanical theory suggests that elevated intraocu-
lar pressure (IOP) is the most important risk factor for 
developing glaucomatous optic neuropathy. However, a 
substantial proportion of patients with primary open-an-
gle glaucoma (POAG) consistently exhibit IOP values 
within the normal range of less than 22 mmHg, or so-
called normal tension glaucoma (NTG) [3]. Moreover, 
POAG may still progress even if IOP is well controlled 
in the low teens [4]. The vascular theory considers 
glaucomatous optic neuropathy a consequence of insuf-
ficient ocular blood supply [5]. Epidemiological studies 
disclosed that low ocular perfusion increases the risk 
for glaucoma [6,7]. Several reports have identified that 
NTG is accompanied by an increased prevalence of 
vascular problems, including hemodynamic crises, hy-
percoagulability, arterial hypertension, arterial hypoten-
sion, high blood viscosity, elevated cholesterol levels, 
Effect of Korean Red Ginseng Supplementation on Ocular Blood Flow in 
Patients with Glaucoma
Na Rae Kim, Ji Hyun Kim, and Chan Yun Kim*
Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine, Seoul 120-752, Korea
The purpose of this study was to evaluate the effect of Korean red ginseng (KRG) on ocular blood flow in patients with 
glaucoma. In a prospective, randomized, placebo-controlled, double-masked crossover trial, 36 patients with open-angle 
glaucoma were consecutively recruited. Subjects were randomly assigned into two groups. Group A received 1.5 g KRG, 
administered orally three times daily for 12 weeks, followed by a wash-out period of 8 weeks and 12 weeks of placebo 
treatment (identical capsules filled with 1.5 g corn starch). Group B underwent the same regimen, but took the placebo first 
and then KRG. Blood pressure, heart rate, and intraocular pressure were measured at baseline and at the end of each phase of 
the study. Visual field examination and ocular blood flow measurements by the Heidelberg Retina Flowmeter were performed 
at baseline and at the end of each phase of the study. Changes in blood pressure, heart rate, intraocular pressure, visual field 
indices, and retinal peripapillary blood flow were evaluated. Blood pressure, heart rate, intraocular pressure, and visual field 
indices did not change after placebo or KRG treatment. After KRG treatment, retinal peripapillary blood flow in the temporal 
peripapillary region significantly improved (p = 0.005). No significant changes were found in retinal peripapillary blood flow 
in either the rim region or the nasal peripapillary region (p = 0.051 and 0.278, respectively). KRG ingestion appears to improve 
retinal peripapillary blood flow in patients with open-angle glaucoma. These results imply that KRG ingestion might be 
helpful for glaucoma management.
Keywords: Panax, Glaucoma, Ocular blood flow, Korean red ginseng, Visual fields
This is an Open Access article distributed under the terms of the Cre-
ative Commons Attribution Non-Commercial License (http://creativecom-
mons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial 
use, distribution, and reproduction in any medium, provided the original 
work is properly cited.
Received 5 Jul. 2010,  Revised 22 Jul. 2010,  Accepted 23 Jul. 2010
DOI:10.5142/jgr.2010.34.3.237 238
J. Ginseng Res. Vol. 34, No. 3, 237-245 (2010)
carotid artery disease, coronary artery disease, migraine, 
vasospasm, low blood velocity, and high resistance in-
dex in the orbital vessels [8-16]. Therefore, improving 
ocular blood flow may help the treatment of glaucoma. 
Several topical and systemic agents have been shown 
to improve ocular circulation in patients with glaucoma 
[17-21].
Ginseng (the root of Panax ginseng C.A. Meyer) has 
been known to be a valuable folk medicine in East Asian 
countries. Red ginseng is produced by steaming raw gin-
seng. Red ginseng is reported to be pharmacologically 
more active than raw ginseng in terms of chemical con-
stituents (Rh4 and Rf2) that are produced in the steaming 
process [22]. In the past few years, the favorable effects 
of Korean red ginseng (KRG) have been reported in nu-
merous diseases, including cardiovascular disease [23-
28], cerebrovascular disease [29], hyperlipidemic disease 
[30,31], sexual dysfunction [32,33], and Alzheimer’s 
disease [34], though the exact explanation for these ef-
fects is not clear. 
Favorable effects of ginseng roots on circulation have 
been reported, but there is no direct evidence that gin-
seng therapy can improve ocular blood flow in patients 
with glaucoma. In the present study, we assessed the ef-
fect of KRG ingestion on ocular blood flow in patients 
with open-angle glaucoma.
MATERIALS AND METHODS
Study design
We recruited 36 consecutive patients (11 men and 25 
women) with open-angle glaucoma between May 2009 
and August 2009. All patients were examined in a pro-
spective, randomized, placebo-controlled, double-blind, 
crossover study. The study was conducted in accor-
dance with the Declaration of Helsinki, and informed 
written consent was obtained from each participant. 
The Institutional Review Board of Severance Hospital, 
Yonsei University approved the study protocol.
Glaucomatous eyes were defined as those with a glau-
comatous VF defect confirmed by two reliable VF exami-
nations and by the appearance of a glaucomatous optic 
disc with typical loss of the neuroretinal rim as judged 
by slit-lamp biomicroscopy (cup-to-disc ratio > 0.7; in-
tereye cup asymmetry > 0.2; or neuroretinal rim notch-
ing, focal thinning, disc hemorrhage, or vertical elonga-
tion of the optic cup). The NTG group was defined as 
those with untreated peak IOP lower than 21 mmHg on 
three repeated measurements taken at different times 
on separate visits during clinical follow-up. The POAG 
group included those with IOP before treatment exceed-
ing 21 mmHg based on three measurements on differ-
ent days. Subjects with a narrow angle, media opacity, 
a history of ocular surgery (other than uncomplicated 
glaucoma and cataract surgery), or other diseases af-
fecting the VF were excluded. 
Subjects who had changed systemic medication with-
in 3 months were excluded, as this may affect blood 
flow. Individuals who were on medications with ginkgo 
biloba extract were excluded. Women of childbearing 
age were also excluded. Participants with controlled 
essential hypertension with stationary systemic medica-
tion were not excluded because of the high prevalence 
of this condition in elderly people. Individuals with 
uncontrolled systemic hypertension above 170 mmHg 
systolic blood pressure or 100 mmHg diastolic pressure 
were excluded.
Administration of Korean red ginseng
KRG (Jeong Kwan Jang; 300 mg/capsule, total 
powder capsule, made by steaming and drying 100% 
6-year-old red ginseng roots) and placebo (identical 
capsules filled with corn starch 95.25%, red ginseng 
fragrance 4.0%, natural food color 0.15%, and caramel 
food color 0.6%) were provided by the Korea Ginseng 
Corporation (Daejeon, Korea). 
Patients were randomly assigned to one of two treat-
ments: oral administration of 1.5 g of KRG three times 
daily for 12 weeks, followed by a washout period of 8 
weeks and then 12 weeks of placebo, or the same scheme, 
but with the placebo first. Eighteen patients were allocated 
to group A (regimen, KRG→washout→placebo) and 18 
to group B (regimen,  placebo→washout→KRG). 
Both participants and study staff (investigators and 
trial-coordinating center staff) were masked to treat-
ment allocation. The order of the drug administration 
was randomized, and the medication was masked and 
coded by the manufacturer. An independent pharma-
cist dispensed either KRG or placebo according to a 
computer-generated, numbered randomization list. The 
KRG and the placebo were identical in appearance 
(shape, size, color, and taste) and in packaging. The 
boxes were labeled with study numbers and recorded in 
a separate database that identified which box contained 
the KRG and the placebo for each study number. These 
data were concealed until study completion.
Measurement of arterial blood pressure and heart 
rate
Blood pressure and heart rate were assessed at base-
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line and at the end of each trial phase. Arterial blood 
pressure was measured on the upper arm by an auto-
mated oscillometric device. Three consecutive read-
ings were obtained 5 minutes apart, and the last two 
were averaged for use in the analysis. Pulse rate was 
automatically recorded by the same device. All exami-
nations were performed with the subject in the sitting 
position.
Intraocular pressure and visual field examinations
IOP was determined with the Goldmann tonometer 
at baseline and at the end of each phase. VF examina-
tions were also performed at the same time. All tests 
were performed using standard automated perimetry 
(Humphrey Field Analyzer II with Swedish interactive 
thresholding algorithm standard 24-2; Carl Zeiss Med-
itec, Dublin, CA, USA). Each test included in the final 
analysis met the reliability criteria set by the manufac-
turer. All VF tests were performed on the same perim-
eter with best correction for near vision for each patient.
Ocular blood flow measurement by the Heidelberg 
Retina Flowmeter 
Ocular blood flow was examined at baseline and at 
the end of each phase. To evaluate ocular blood flow, 
peripapillary retinal blood flow was obtained using 
the Heidelberg Retina Flowmeter (HRF; Heidelberg 
Engineering, Heidelberg, Germany). The technique of 
scanning laser Doppler flowmetry (SLDF) on the HRF 
has been described in detail elsewhere [35,36]. Briefly, 
the examination was performed in the sitting position 
without pupillary dilation after a short rest (about 10 
to 15 minutes) at room temperature and with diffuse 
natural light. The laser Doppler frequency shift was 
measured by SLDF in each of 16,384 points in a retinal 
area of 2.7 × 0.7 mM within 2 seconds. Confocal optics 
of this device registered only the capillary blood flow 
of the superficial retinal layer of 300 μm. Detection 
of laser Doppler signals from deeper layers (choroid) 
was excluded due to the confocal characteristics of the 
optics. A map of the retinal blood flow was generated, 
encoded by the laser Doppler shift. Spatial resolution of 
the device was 10 × 10 μm. The HRF scanned an inten-
sity matrix of 256 points × 68 lines × 128 times using a 
repetition rate of 4,000 Hz. Backscattered intensities of 
each scanned point were obtained as a function of time, 
resulting in 16,384 intensity–time curves. Collected in-
tensity data of each retinal point of measurement were 
analyzed by discrete fast Fourier transformation, calcu-
lating the frequency laser Doppler shift for each point 
of measurement.
Acquired perfusion images were analyzed with au-
tomatic full-field evaluation of the perfusion images 
(SLDF-AFFPIA) [37,38]. SLDF-AFFPIA was used to 
analyze the perfusion images off-line after the experi-
ments. For valid estimation of retinal blood flow by HRF, 
some requirements must be fulfilled: adequate brightness, 
no artificial movement, and a Doppler shift lower than 
2,000 Hz. To meet these requirements, the resultant 
perfusion images were processed by the SLDF-AFFPIA 
with respect to underexposed and overexposed pixels, 
saccades, and retinal vessel tree. In the first step of the 
statistical analysis, the operator marked saccades and 
the location of the rim area. In the second step, capillar-
ies and vessels of the retinal vessel tree were identified 
automatically by a vessel detection algorithm based on 
the intensity and the perfusion image. After these pro-
cedures, retinal vessels with diameters larger than 30 
μm, underexposed or overexposed pixels, and saccades 
were automatically excluded from the perfusion image. 
These processes led to a perfusion map with vessels 
smaller than 30 μm in diameter, without lines caused by 
saccades, and without pixels of inadequate reflectivity. 
Based on this processed perfusion map and all flow val-
ues, SLDF-AFFPIA automatically calculated the mean 
flow, SD, and cumulative frequency distribution curve 
in the scanned retinal area.
Ten images for each eye were acquired by a single op-
erator, and the average value was used for analysis of 
retinal blood flow to improve reproducibility. When the 
operator drew the inner and outer rim contour lines, the 
program automatically calculated the flow. In each HRF 
image, the central rim area and the adjacent temporal 
and nasal peripapillary areas were analyzed by the AF-
FPIA program. All optic nerve heads (ONHs) were 
theoretically divided into three horizontal sections 
(superior, central, and inferior sections) (Fig. 1). In this 
study, only central ONH sections were considered.
Statistical analysis
For statistical analysis, one eye of each patient was 
randomly selected. Statistical analyses of the data were 
performed using the Wilcoxon signed-rank test, compar-
ing blood pressure, heart rate, IOP, VF indices (including 
mean deviation and pattern standard deviation), and reti-
nal blood flow parameters for each phase of the study. 
The Wilcoxon rank-sum test was used for the compari-
son of the two groups. Statistical analysis was performed 
using SPSS ver. 12.0 (SPSS Inc, Chicago, IL, USA). A 
p-value of less than 0.05 was considered significant.
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RESULTS
Subjects
All participants successfully completed the study. 
The mean age was 59.03 ± 12.47 years. Participants 
were 24 NTG patients (66.7%) and 12 POAG patients 
(33.3%) (Table 1).
Thirty-one patients (86.1%) used topical antiglau-
coma agents. The mean number of topical antiglaucoma 
agents used by each patient was 1.23±0.84. Twenty-two 
patients (61.1%) took systemic concomitant medication. 
Five patients took low-dose acetylsalicylic acid, and 13 
patients took anti-hypertensive medications (Table 2).  
One patient complained of feeling feverish after KRG 
treatment, and two patients complained of feeling bloated 
after placebo treatment. No significant side effects related 
to KRG were found in this study.
Blood pressure and heart rate
The mean systolic blood pressure was 130.42 ± 14.17 
Fig. 1. (A) All optic nerve heads (ONHs) were theoretically divided into three horizontal sections (superior, central, and inferior). In this study, only central 
ONH sections were considered. (B) For each perfusion map, the automatic full-field evaluation of the perfusion images calculated three different flow mea-
surements (rim flow, adjacent temporal flow, and adjacent nasal retinal flow) after drawing the inner and outer rim contour lines.
Table 1. Baseline characteristics of patients studied
Variable All (n=36)
No. of patients 36
Age (yr)  59.03±12.47
Female (n, %) 25 (69.4)
Diastolic BP (mmHg) 72.28±8.78
Systolic BP (mmHg) 130.42±14.17
Heart rate (bpm)  74.69±10.13
Height (cm) 159.20±6.38
Body weight (kg) 58.66±9.53
Body mass index (kg/m2) 23.05±2.68
Glaucoma diagnosis
   Normal tension glaucoma (n, %) 24 (66.7)
   Primary open angle glaucoma (n, %) 12 (33.3)
Data presented are mean±SD unless otherwise noted.
BP, blood pressure; bpm, beats per minute.
Table 2. Ocular medications and systemic medications used in pa-
tients with glaucoma
Number
Topical medication Betaxolol 2
Brimonidine 1
Brinzolamide 6
Dorzolamide 1
Bimatoprost 1
Latanoprost 12
Travoprost 6
Timolol 1
Timolol + brinzolamide 1
Timolol + dorzolamide 5
Timolol + latanoprost 1
Systemic medication Acetylsalicylic acid (low-dose) 5
Alpha adrenergic blocking agents 1
Angiotensin II receptor antagonist 8
Beta adrenergic blocking agents 5
Calcium-channel blockers 2
Dihydropyridines 1
Fibric acid derivatives 1
Levothyroxine 4
Statins 6
Thiazid diuretics 2
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mmHg, and the mean heart rate was 74.69 ± 10.13 beats/
min at baseline. KRG did not alter systemic arterial 
blood pressure in either KRG or placebo phases. No 
significant modifications in heart rate were noted after 
either KRG or placebo phases (Table 3). 
Intraocular pressure and visual field indices
There were no significant changes in IOP or VF indi-
ces after either KRG or placebo phases (Table 4).
Retinal blood flow
For the rim and nasal area flow, no difference was 
found between baseline and 12 weeks of KRG treat-
ment. However, a significant difference was found in 
temporal area flow. After the KRG phase, group A (18 
patients) showed a significant difference in the blood 
flow of the temporal peripapillary area when compared 
with the baseline values (baseline vs. after KRG, 420.24 
vs. 440.65 [median, no units], p = 0.039). After the placebo 
phase, no significant modifications were detected when 
compared with the baseline (p = 0.877) (Table 5). After the 
placebo phase, group B showed no significant changes in 
blood flow parameters compared with the baseline values 
(p = 0.679). After the KRG phase, blood flow in the tem-
poral peripapillary area significantly improved when com-
pared with the baseline (baseline vs. after KRG, 415.85 vs. 
459.36 [median, no units], p = 0.048) (Table 5).
When all eyes of groups A and B were pooled and 
compared with pooled baseline values, a significant im-
provement was noted in retinal blood flow in the tem-
poral peripapillary area after KRG treatment (p = 0.005). 
No significant changes were found in retinal peripapil-
lary blood flow in the rim region or the nasal peripapil-
lary region (p = 0.051 and 0.278, respectively) (Table 5). 
DISCUSSION
It is generally agreed that risk factors in addition to 
ocular hypertension may play an important role in the 
pathogenesis of open-angle glaucoma. According to the 
vascular or ischemic hypothesis, glaucomatous damage 
is caused, or at least facilitated, by inadequate perfusion 
of the proximal portion of the optic nerve. Findings that 
suggest vascular or perfusion abnormalities in NTG 
include an increased frequency of migraine headaches 
[10,11] and Raynaud’s phenomenon [8]. In support of 
a vascular role in NTG, Tokunaga et al. [16] found that 
NTG patients with a dip of more than 20% in nocturnal 
blood pressure had a higher incidence of VF progres-
sion than did those with a more physiologic dip of 10 to 
Table 3. Blood pressure and heart rate responses after each phase of the study (patients are divided in two groups according to sequences of 
treatment)
Group A (n=18) Group B (n=18)
Baseline Ginseng p-value1) Placebo p-value1) Baseline Placebo p-value1) Ginseng p-value1)
Diastolic BP 
(mmHg)
70.00
(66.75–80.00)
70.00
(62.50–75.00)
0.058 71.00
(62.50–78.00)
0.727 71.50
(65.75–77.50)
69.00
(66.00–72.25)
0.379 73.00
(68.75–78.25)
0.368
Systolic BP 
(mmHg)
123.50
(114.75–138.50)
124.50
(113.50–130.00)
0.074 128.00
(115.25–137.75)
0.844 127.50
(118.75–137.25)
124.50
(114.50–133.00)
0.078 131.00
(123.25–136.75)
0.407
Heart rate 
(bpm)
73.50
(65.50–83.50)
73.50
(64.50–85.25)
0.981 77.00
(67.00–87.00)
0.093 74.00
(71.50–82.25)
78.00
(72.50–89.00)
0.107 81.00
(70.75–91.50)
0.076
Group A sequence of treatment, ginseng➙washout➙placebo; group B sequence of treatment, placebo➙washout➙ginseng.
Data presented are median (interquartile range).
BP, blood pressure; bpm, beats per minute.
1)Values for comparison with baseline (Wilcoxon signed-rank test).
Table 4. Intraocular pressure and visual field indices after each phase of the study (patients are divided in two groups according to sequences 
of treatment)
Group A (n=18) Group B (n=18)
Baseline Ginseng p-value1) Placebo p-value1) Baseline Placebo p-value1) Ginseng p-value1)
IOP (mmHg)
13.50
(12.00–15.00)
13.50
(11.75–14.25)
0.586 13.00
(10.75–15.00)
0.145 14.00
(12.00–16.00)
13.00
(12.00–14.00)
0.496 13.50
(11.75–15.00)
0.404
MD (dB)
-4.22
(-6.13– -1.53)
-4.14
(-6.18– -1.95)
0.420 -4.53
(-7.13– -2.91)
0.420 -2.59
(-4.64– -1.07)
-2.41
(-3.97– -0.87)
0.372 -2.57
(-4.79– -1.17)
0.913
PSD (dB)
2.21
(1.50–6.96)
2.16
(1.73–7.01)
0.586 2.40
(1.64–6.30)
0.845 1.93
(1.51–3.87)
1.80
(1.56–6.26)
0.556 1.77
(1.56–2.68)
0.896
Group A sequence of treatment, ginseng➙washout➙placebo; group B sequence of treatment, placebo➙washout➙ginseng.
Data presented are median (interquartile range).
IOP, intraocular pressure; MD, mean deviation; dB, decibel; PSD, pattern standard deviation.
1)Values for comparison with baseline (Wilcoxon signed-rank test).
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20%. Systemic hypotension may also have a deleterious 
effect by creating insufficient perfusion pressure in the 
optic disc [14,15].
The vasoactive effect could be useful in glaucoma; there 
is growing evidence that in some patients, glaucoma is 
associated with vascular dysregulation and lower perfu-
sion pressure. Many authors have shown that vascular 
resistance downstream from the central retinal and pos-
terior ciliary arteries is increased in glaucoma [5,10,13-
15]. Several studies have shown blood flow or blood 
velocity differences between normal, healthy subjects 
and glaucomatous ones [39,40]. Improving ocular blood 
flow together with reducing IOP may have a rationale 
in the treatment of glaucoma.
Several techniques for ocular blood flow evaluation 
have been introduced to clinical ophthalmology. How-
ever, these techniques have shown an uncertain reliabil-
ity. In addition, it has not been determined which he-
modynamic variables of blood supply (i.e., ophthalmic 
artery, posterior ciliary arteries, or central retinal artery) 
are appropriate to investigate with respect to the patho-
genetic aspects of glaucoma. In this study, we utilized 
a commonly used SLDF device, HRF, which measures 
peripapillary retinal blood flow. Previous studies us-
ing HRF have reported significant decreases in ONH 
blood flow and juxtapapillary blood flow in open-angle 
glaucoma [41-43]. Because HRF takes 2 sec to capture 
a topographic image when working from the top left 
to the bottom right [36], the resulting image is subject 
to special heterogeneity in circulatory parameters due 
to heart beat-associated pulsations [44]. Newer im-
age software (AFFPIA) that uses the entire field of 
topographic images was reported to improve reliability 
[37,45-47]. The AFFPIA full-field option provides the 
highest reliability because it includes the largest pos-
sible image area for analysis and automatically adjusts 
for the quality of the topographic image, “auto-cleaning” 
and masking any extra-wide vessels, ONH, and over- or 
under-exposed pixels [37]. In addition, each measure-
ment was performed ten times in a chosen region to 
improve accuracy in ocular blood flow assessment. 
KRG has been demonstrated to be effective in nu-
merous vascular diseases [23-34]. The authors believed 
that KRG supplementation in open-angle glaucoma 
patients might be helpful for improving ocular blood 
flow. Theoretically, it may provide a protective effect on 
glaucoma progression. Our study using HRF to measure 
ocular blood flow suggests that KRG administration 
can be beneficial for retinal peripapillary blood flow in 
the temporal area in patients with open-angle glaucoma. 
Table 5. Blood flow parameters after each phase of the study and after cross-over trial
Group A (n=18)
Baseline Ginseng p-value1) Placebo p-value1)
Temporal peripapillary area 420.24
(322.92 – 523.41)
440.65
(336.15 – 626.24)
0.039 375.27
(260.50 – 615.33)
0.877
Neuroretinal rim area
411.53
(291.99 – 531.53)
442.42
(336.99 – 642.57)
0.078 384.88
(236.45 – 482.78)
0.959
Nasal peripapillary area
305.21
(224.71 – 455.84)
323.97
(236.07 – 503.53)
0.647 279.08
(224.24 – 415.69)
0.910
Group B (n=18)
Baseline Placebo p-value1) Ginseng p-value1)
Temporal peripapillary area 415.85
(337.50 – 552.49)
395.95
(322.79 – 470.35)
0.679 459.36
(360-94 – 696.56)
0.048
Neuroretinal rim area
371.68
(287.50 – 515.89)
325.43
(246.48 – 410.28)
0.472 372.52
(312.02 – 552.24)
0.267
Nasal peripapillary area 
302.68
(222.44 – 477.36)
266.95
(240.71 – 355.06)
0.528 319.21
(222.81 – 454.19)
0.349
All (n=36)
Baseline Ginseng p-value1) Placebo p-value1) p-value2)
Temporal peripapillary area 415.85
(333.91-531.12)
459.36
(345.95-681.65)
0.005 393.93
(290.03-478.69)
0.898 0.039
Neuroretinal rim area
386.91
(299.61-523.66)
395.22
(324.13-566.91)
0.051 360.11
(251.02-444.44)
0.510 0.066
Nasal peripapillary area 
302.68
(227.55-462.64)
320.44
(232.35-462.40)
0.278 269.97
(239.60-392.10)
0.598 0.255
Group A sequence of treatment, ginseng➙washout➙placebo; group B sequence of treatment, placebo➙washout➙ginseng.
Data presented are median (interquartile range).
1)Values for comparison with baseline (Wilcoxon signed-rank test).
2)Values for comparing ginseng and placebo (Wilcoxon rank-sum test).
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However, in the nasal peripapillary and rim areas, no 
difference was found. Differences in IOP, systemic 
blood pressure, and VF indices before and after KRG 
administration were not significant. In addition, perfu-
sion pressure measured before KRG administration did 
not change after KRG administration (data not shown 
here). It is not certain to what extent favorable influence 
could be exerted on preventing disease progression by 
the improvement of ocular blood flow in the confined 
juxtapapillary temporal area. In addition, the reason that 
a significant difference after KRG administration was 
found only in the temporal peripapillary area should be 
further studied. 
This study has several limitations that require consid-
eration. First, the limited duration of our study did not 
allow us to predict how long the effects of KRG admin-
istration would last. The duration of the effect and op-
timal administration schedule for KRG treatment must 
be investigated in future studies of glaucoma patients. An-
other limitation of this study is the large number of partici-
pants who used systemic medication. However, only pa-
tients whose systemic medication had not changed over 
the previous three months were enrolled to minimize 
the effect on ocular blood flow. In addition, the phar-
macological agents taken by the participants in this trial 
stem from many different classes, and the small number 
of vasoactive substances used may have little implica-
tion on the results of this study. The use of topical anti-
glaucomatous therapy may also have affected the study 
results, but the effects are generally considered small. 
Third, HRF system measurements reflect only retinal 
blood flow. As mentioned above, it is unknown which 
source of blood flow plays a key role in the pathogen-
esis of glaucoma. Various techniques for the evaluation 
of ocular blood flow, including in the ophthalmic artery, 
short posterior ciliary arteries, and the central retinal 
artery, could strengthen the results of this study. Finally, 
the main limitation of this study is the small sample 
size. To distinguish the difference in ocular blood flow 
after ginseng treatment, 25 patients should have been 
recruited for each group, which would have provided 
sufficient statistical power to detect differences of 60 (no 
unit) (α = 0.05 and β = 20%). The present study is lim-
ited in terms of detecting significant differences in ocu-
lar blood flow after ginseng treatment. However, it was 
difficult to calculate appropriate sample sizes based on 
limited knowledge of the effect of ginseng treatment on 
ocular blood flow. More comprehensive analysis needs 
to be performed with a larger population.
In conclusion, significant increases in retinal blood 
flow were found in the temporal peripapillary areas af-
ter treatment with KRG as measured by HRF. Because 
numerous risk factors of a vascular nature have been 
reported to contribute to the pathogenesis of glaucoma, 
treatment to improve the ocular blood flow has some 
possibility of being helpful to prevent glaucoma pro-
gression. However, the effect is unpredictable because 
it has not been determined which source of blood sup-
ply affects glaucoma progression. A long-term prospec-
tive, placebo-controlled, randomized trial that takes into 
account the effects of KRG on glaucoma progression is 
warranted to investigate whether KRG is truly benefi-
cial as a systemic treatment for glaucoma.
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